Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab-Reference-Cited by-同舟云学术

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

Published:2021-06 Issue: Volume:57 Page:80-85
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

De Sanctis Rita,Giordano Laura,D’Antonio Federica,Agostinetto Elisa^ORCID,Marinello Arianna^ORCID,Guiducci Daniela,Masci Giovanna,Losurdo Agnese^ORCID,Zuradelli Monica,Torrisi Rosalba,Santoro Armando

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference31 articles.

1. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

2. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

3. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial;Cameron;Lancet,2017

4. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials;Niraula;Breast Canc Res Treat,2019

5. Trastuzumab cardiotoxicity: from clinical trials to experimental studies;Nemeth;Br J Pharmacol,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer;Toxicological Research;2024-04-22

2. Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer;International Journal of Breast Cancer;2024-01

3. Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka;BMC Cancer;2023-03-04

4. Preventive effect of dexamethasone premedication on the development of infusion‐related reaction in breast cancer patients receiving trastuzumab;British Journal of Clinical Pharmacology;2023-02-09

5. Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?;Cancers;2022-12-29